New AFib recommendations from the American College of Cardiology and American Heart Association covered significant ground—but there is still much more to learn, experts explained. 

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

The device is intended to be a bridge for heart failure patients waiting to receive a full heart transplant.

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

The research will focus on ways to improve the utilization of electronic resources among heart failure patients and the doctors who treat them.

Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.

The technology may not be cheap, but new research published in The American Journal of Cardiology suggests the investment is well worth it. 

The FDA considers this a Class I recall, which means using the impacted devices “may cause serious injuries or death.” One patient injury has been reported at this time.